@article {Fowotade2022.02.03.22270152, author = {Adeola Fowotade and Folasade Bamidele and Boluwatife Egbetola and Adeniyi Francis Fagbamigbe and Babatunde Ayodeji Adeagbo and Bolanle Olufunlola Adefuye and Ajibola Olagunoye and Temitope Olumuyiwa Ojo and Akindele Olupelumi Adebiyi and Omobolanle Ibitayo Olagunju and Olabode Taiwo Ladipo and Abdulafeez Akinloye and Adedeji Onayade and Oluseye Oladotun Bolaji and Steve Rannard and Christian Happi and Andrew Owen and Adeniyi Olagunju}, title = {Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19}, elocation-id = {2022.02.03.22270152}, year = {2022}, doi = {10.1101/2022.02.03.22270152}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Finding effective therapeutics for COVID-19 continues to be an urgent need, especially considering use context limitations and high cost of currently approved agents. The NACOVID trial investigated the efficacy and safety of repurposed antiprotozoal and antiretroviral drugs, nitazoxanide and atazanavir/ritonavir, used in combination for COVID-19.Methods In this pilot, randomized, open-label trial conducted in Nigeria, patients diagnosed with mild to moderate COVID-19 were randomly assigned to receive standard of care (SoC) or SoC plus a 14-day course of nitazoxanide (1000 mg b.i.d.) and atazanavir/ritonavir (300/100 mg od) and followed through day 28. Study endpoints included time to clinical improvement, SARS-CoV-2 viral load change, and time to complete symptom resolution. Safety and pharmacokinetics of nitazoxanide active metabolite, tizoxanide, were also evaluated. This trial was registered with ClinicalTrials.gov (NCT04459286).Findings There was no difference in time to clinical improvement between the SoC (n = 26) and SoC plus intervention arms (n = 31; Cox proportional hazards regression analysis adjusted hazard ratio, aHR = 0.898, 95\% CI: 0.492-1.638, p = 0.725). No difference was observed in the pattern of saliva SARS-CoV-2 viral load changes from days 2 to 28 in the 35\% of patients with detectable virus at baseline (20/57) between the two arms (aHR = 0.948, 95\% CI: 0.341-2.636, p = 0.919). There was no significant difference in time from enrolment to complete symptom resolution (aHR = 0.535, 95\% CI: 0.251 - 1.140, p = 0.105). Atazanavir/ritonavir increased tizoxanide plasma exposure by 68\% and median trough plasma concentration was 1546 ng/ml (95\% CI: 797-2557), above its putative EC90 in 54\% of patients. Tizoxanide was not detectable in saliva.Interpretation These findings should be interpreted in the context of incomplete enrolment (64\%) and the limited number of patients with detectable SARS-CoV-2 in saliva at baseline in this trial.Funding The University of Liverpool.Evidence before this study The potential efficacy of nitazoxanide as a repurposed drug for COVID-19 is being investigated in a number of studies due to confirmed in vitro activity against SARS-CoV-2. Available data from completed randomised controlled trials in which clinical improvement, effect on viral load, and symptom resolution were evaluated as outcomes do not offer conclusive evidence.Added value of this study In the NACOVID trial, we sought to take advantage of a model-informed strategy and known interaction between nitazoxanide and atazanavir/ritonavir to achieve optimal concentration of tizoxanide in plasma, and possibly in respiratory tracts of patients with mild to moderate COVID-19. While this strategy significantly enhanced tizoxanide exposure in the plasma of patients, our data indicated poor penetration into the respiratory tracts. Specifically, there were no differences in time to clinical improvement, viral load changes, and symptom resolutions between patients who were given standard of care alone and those who combined it with study intervention.Implications of all the available evidence The clinical benefit of nitazoxanide remains uncertain. The present study highlights the need for early insight into target site biodistribution of potential COVID-19 therapeutics to better inform candidate selection for clinical trials.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04459286Clinical Protocols https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04987-8 Funding StatementThis trial was funded internally by the University of Liverpool and no additional external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Health Research Ethics Committee, Nigeria (approval number: NHREC/01/01/2007-26/08/2020) and the Central University Research Ethics Committee, University of Liverpool (reference number: 8074) approved the protocol. The National Agency for Food and Drug Administration and Control in Nigeria gave regulatory approval for the trial.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.}, URL = {https://www.medrxiv.org/content/early/2022/02/04/2022.02.03.22270152}, eprint = {https://www.medrxiv.org/content/early/2022/02/04/2022.02.03.22270152.full.pdf}, journal = {medRxiv} }